Back to Directory

Rachel Scheckter

Email

rscheckter@fhi360.org

Phone

919-321-3540

Institution

FHI 360

Address

FHI 360
359 Blackwell St.
Ste. 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected Children >2 to <12 years of age and weighing >10 kgs and <50 kgs

DAIDS Number

Research Area

Study Status

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

Research Area

Study Status

Closed to Accrual

P1110: Safety and PK of RAL in Neonates

DAIDS Number

Research Area

P1097: Raltegravir PK Study

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed